Case-control breast cancer study of MALDI-TOF proteomic mass spectrometry data on serum samples.
We introduce mass spectrometry proteomic research for diagnosis from a clinical perspective, with special reference to early-stage breast cancer detection. The nature of SELDI and MALDI mass spectrometric measurement is discussed. We explain how the mass spectral data arising from this technology may be viewed as a new data type. Some of the properties of the data are discussed and we show how such spectra may be interpreted. Sample preprocessing for mass spectrometry is introduced and a literature review of research in clinical proteomics is presented. Finally, we provide a detailed description of the study design on the breast cancer case-control study which is investigated in this special issue.
van der Werff
Martijn P J
MP
Leiden University Medical Center. m.p.j.van der werff@lumc.nl
Mertens
Bart
B
de Noo
Mirre E
ME
Bladergroen
Marco R
MR
Dalebout
Hans C
HC
Tollenaar
Rob A E M
RA
Deelder
Andre M
AM
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001943:Breast Neoplasms / Q000175:diagnosis / Q000378:metabolism*; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D008875:Middle Aged; D040901:Proteomics; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
D014408:Biomarkers, Tumor